Monday , February 26 2018
Home / Therapies / SGLT-2 Therapy Center (page 13)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Christophe Arbet-Engels, MD, Q1: Empagliflozin Studies Results

Dr. Christophe Arbet-Engels, discusses some of the study results on empagliflozin in which more than 14,000 patients were involved in several different study configurations including monotherapy, empagliflozin as an add-on, and patients with renal impairment.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer …

Read More »

Christophe Arbet-Engels, MD, Q10: Possibility of Combination Drugs with Empagliflozin

Dr. Christophe Arbet-Engels continues his discussion of the potential for combining the SGLT-2 inhibitor empagliflozin with other drugs down the road, and that they will certainly be exploring these otpions.  Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Read More »

Christophe Arbet-Engels, MD, Q11: Is Empagliflozin Also Being Submitted Internationally?

Dr. Christophe Arbet-Engels explains that Boehringer Ingelheim will also be submitting empagliflozin internationally, and certainly in the EU, and that they will also look carefully at all possibilities to submit the drug to other international authorities. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim …

Read More »